AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15587767 — intervention group
Group type: EXPERIMENTAL
Intervention: pioglitazone
Number of subjects: 3713
Study 11733254 — intervention group
Group type: EXPERIMENTAL
Intervention: Two Surodex pellets inserted in the anterior chamber (AC) of 35 eyes (group B)
Number of subjects: 104
Study 11733254 — intervention group
Group type: EXPERIMENTAL
Intervention: Two Surodex pellets inserted in the ciliary sulcus of 36 eyes (group C)
Number of subjects: 104
Study 11733254 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone eyedrops (0.1%) four times daily for 4 weeks (group A)
Number of subjects: 104
Study 9441102 — intervention group
Group type: EXPERIMENTAL
Intervention: KRM 1648 (KRM) at 20 micrograms/ml
Number of subjects: 0
Study 9441102 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin (RBT) at 20 micrograms/ml
Number of subjects: 0
Study 9441102 — intervention group
Group type: EXPERIMENTAL
Intervention: KRM 1648 (KRM) at 0.2 microgram/ml combined with 2.0 micrograms/ml of CLA
Number of subjects: 0
Study 9441102 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin (RBT) at 0.2 microgram/ml combined with 2.0 micrograms/ml of CLA
Number of subjects: 0
Study 7950502 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipriflavone (600 mg/day, tdd) with 500 mg/day of calcium
Number of subjects: 39
Study 7950502 — intervention group
Group type: COMPARATOR
Intervention: Placebo with 500 mg/day of calcium
Number of subjects: 39
Study 2888551 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyrotrophin binding inhibiting (TBII) antibodies
Number of subjects: 60
Study 2888551 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid stimulating (TSAb) antibodies
Number of subjects: 60
Study 2888551 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid growth stimulating (TGI) antibodies
Number of subjects: 60
Study 2888551 — intervention group
Group type: EXPERIMENTAL
Intervention: TBII and TSAb
Number of subjects: 60
Study 31540869 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar electrocautery technique
Number of subjects: 534
Study 31540869 — intervention group
Group type: COMPARATOR
Intervention: Cold dissection technique
Number of subjects: 534
Study 30061588 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Bifidobacterium animalis subsp. lactis Bl‐04
Number of subjects: 0
Study 30061588 — intervention group
Group type: COMPARATOR
Intervention: Rhinovirus infection
Number of subjects: 0
Study 28490348 — intervention group
Group type: EXPERIMENTAL
Intervention: MammaTyper® test for determining mRNA expression levels of ERBB2, ESR1, PGR, and MKI67
Number of subjects: 10
Study 28490348 — intervention group
Group type: EXPERIMENTAL
Intervention: MammaTyper® test for binary single-marker results (positive/negative)
Number of subjects: 10
Study 26292908 — intervention group
Group type: EXPERIMENTAL
Intervention: POCT urine culture and susceptibility testing and targeted treatment
Number of subjects: 750
Study 26292908 — intervention group
Group type: COMPARATOR
Intervention: POCT urine culture without susceptibility testing and empirical treatment
Number of subjects: 750
Study 23811325 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep restriction involving a fixed sleep-wake schedule, reducing time in bed (TIB) by 60 minutes below baseline for older long sleepers.
Number of subjects: 200
Study 23811325 — intervention group
Group type: COMPARATOR
Intervention: Control treatment involving no sleep restriction but a fixed sleep schedule for older average sleepers.
Number of subjects: 200
Study 21399490 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (4 mg · kg⁻¹ · h⁻¹)
Number of subjects: 63
Study 21399490 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane (1 minimum alveolar concentration)
Number of subjects: 63
Study 21399490 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (1 minimum alveolar concentration)
Number of subjects: 63
Study 21399490 — intervention group
Group type: EXPERIMENTAL
Intervention: All anesthetics (Propofol, Desflurane, Sevoflurane)
Number of subjects: 63
Study 21399490 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane and Sevoflurane
Number of subjects: 63
Study 18721764 — intervention group
Group type: EXPERIMENTAL
Intervention: palifermin (240 microg/kg to 720 microg/kg)
Number of subjects: 100
Study 18721764 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 100
Study 16837678 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (200 mg on the first day, then 100 mg per day for four days)
Number of subjects: 93
Study 16837678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 15570767 — intervention group
Group type: EXPERIMENTAL
Intervention: LASEK
Number of subjects: 14
Study 15570767 — intervention group
Group type: COMPARATOR
Intervention: PRK
Number of subjects: 14
Study 11083601 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.5 mg)
Number of subjects: 6
Study 11083601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 9036434 — intervention group
Group type: EXPERIMENTAL
Intervention: 21-G pencil-point needle (Sprotte)
Number of subjects: 412
Study 9036434 — intervention group
Group type: COMPARATOR
Intervention: 22-G Quincke needle
Number of subjects: 412
Study 1573199 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training program based on figural relations, a component of fluid intelligence.
Number of subjects: 0
Study 1573199 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study 3887210 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet antiaggregant therapy
Number of subjects: 0
Study 3887210 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 0
Study 30791895 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (50,000 IU every 2 weeks) plus probiotic (8 × 10^9 CFU/day)
Number of subjects: 60
Study 28177459 — intervention group
Group type: EXPERIMENTAL
Intervention: NOAC
Number of subjects: 22198
Study 25236682 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound closure in flexion position
Number of subjects: 85
Study 25236682 — intervention group
Group type: COMPARATOR
Intervention: Wound closure in extension position
Number of subjects: 85
Study 25365713 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for spinal stenosis
Number of subjects: 634
Study 25365713 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for degenerative spondylolisthesis (DS)
Number of subjects: 634
Study 25365713 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for intervertebral disc herniation (IDH)
Number of subjects: 634
Study 25365713 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment for degenerative spondylolisthesis (DS)
Number of subjects: 634
Study 25365713 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment for intervertebral disc herniation (IDH)
Number of subjects: 634
Study 22295835 — intervention group
Group type: EXPERIMENTAL
Intervention: SXDZ-100
Number of subjects: 64
Study 22295835 — intervention group
Group type: COMPARATOR
Intervention: SDZ-II
Number of subjects: 64
Study 21152844 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol
Number of subjects: 160
Study 21152844 — intervention group
Group type: COMPARATOR
Intervention: Foley catheter
Number of subjects: 160
Study 21152844 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 160
Study 17347061 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone diproprionate enema
Number of subjects: 99
Study 17347061 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone diproprionate foam
Number of subjects: 99
Study 17347061 — intervention group
Group type: COMPARATOR
Intervention: Mesalazine enema
Number of subjects: 99
Study 17347061 — intervention group
Group type: COMPARATOR
Intervention: Mesalazine foam
Number of subjects: 99
Study 16092810 — intervention group
Group type: EXPERIMENTAL
Intervention: CAM education and research integration
Number of subjects: 0
Study 16092810 — intervention group
Group type: EXPERIMENTAL
Intervention: Setting educational standards for CAM
Number of subjects: 0
Study 12222716 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam sedation
Number of subjects: 50
Study 12222716 — intervention group
Group type: COMPARATOR
Intervention: Rectal midazolam sedation
Number of subjects: 50
Study 10512347 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 6
Study 10512347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 7734163 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic therapy with amoxicillin and clavulanic acid for 24 hours
Number of subjects: 170
Study 7734163 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic therapy with amoxicillin and clavulanic acid for 5 days
Number of subjects: 170
Study 1979288 — intervention group
Group type: EXPERIMENTAL
Intervention: Buserelin (Gn-RH superagonist)
Number of subjects: 48
Study 1979288 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 48
Study 1979288 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA)
Number of subjects: 48
Study 1979288 — intervention group
Group type: COMPARATOR
Intervention: Control group (post-buserelin observation)
Number of subjects: 48
Study 7004556 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium
Number of subjects: 98
Study 7004556 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol/dextropropoxyphene combination
Number of subjects: 98
Study 29399709 — intervention group
Group type: EXPERIMENTAL
Intervention: Undistracted group (Group 1)
Number of subjects: 20
Study 29399709 — intervention group
Group type: COMPARATOR
Intervention: Distracted group (Group 2)
Number of subjects: 20
Study 27015801 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal high flow (NHF) at 30 L/min
Number of subjects: 30
Study 27015801 — intervention group
Group type: COMPARATOR
Intervention: Long-term oxygen therapy (LTOT) at 2‐4 L/min
Number of subjects: 30
Study 25769334 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforced health education
Number of subjects: 106
Study 25769334 — intervention group
Group type: COMPARATOR
Intervention: Traditional health education
Number of subjects: 106
Study 23841289 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-ligating brackets
Number of subjects: 30
Study 23841289 — intervention group
Group type: COMPARATOR
Intervention: Conventional brackets
Number of subjects: 30
Study 20579583 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery revascularization before elective vascular surgery
Number of subjects: 30
Study 20579583 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline homocysteine level
Number of subjects: 30
Study 18256366 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (blood pressure lowering regimen)
Number of subjects: 5671
Study 18256366 — intervention group
Group type: EXPERIMENTAL
Intervention: Carriers of epsilon 2 or epsilon 4 allele of the APOE polymorphism
Number of subjects: 5671
Study 18256366 — intervention group
Group type: EXPERIMENTAL
Intervention: Carriers of epsilon 2 or epsilon 4 allele in Asian patients
Number of subjects: 5671
Study 18256366 — intervention group
Group type: EXPERIMENTAL
Intervention: Carriers of epsilon 2 or epsilon 4 allele in Europeans
Number of subjects: 5671
Study 16456897 — intervention group
Group type: EXPERIMENTAL
Intervention: Oltipraz
Number of subjects: 0
Study 16456897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12030636 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior experiences expectation measure
Number of subjects: 315
Study 12030636 — intervention group
Group type: EXPERIMENTAL
Intervention: Ideal referents expectation measure
Number of subjects: 315
Study 12030636 — intervention group
Group type: EXPERIMENTAL
Intervention: Market-based expectations measure
Number of subjects: 315
Study 9835830 — intervention group
Group type: EXPERIMENTAL
Intervention: Crest MultiCare with 3.3% pyrophosphate
Number of subjects: 456
Study 9835830 — intervention group
Group type: COMPARATOR
Intervention: Crest Regular Paste or Crest Tartar Protection Paste with 5.0% pyrophosphate
Number of subjects: 456
Study 8007590 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low protein diet (VLPD) with ketoacids (KA)
Number of subjects: 8
Study 8007590 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low protein diet (VLPD) with essential amino acids (EAA)
Number of subjects: 8
Study 8007590 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low protein diet (VLPD)
Number of subjects: 8
Study 2643188 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of 2 grams of ampicillin at the site of incision at closure
Number of subjects: 193
Study 2643188 — intervention group
Group type: COMPARATOR
Intervention: No topical application of ampicillin
Number of subjects: 193
Study 2643188 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of ampicillin
Number of subjects: 193
Study 8291727 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltanolone
Number of subjects: 175
Study 8291727 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 175
Study 8291727 — intervention group
Group type: COMPARATOR
Intervention: Thiopental
Number of subjects: 175
Study 377739 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 2.4 g daily
Number of subjects: 60
Study 377739 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol 200 mg daily
Number of subjects: 60
Study 377739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31485815 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric Developmental Passport
Number of subjects: 40
Study 31485815 — intervention group
Group type: COMPARATOR
Intervention: Placebo card
Number of subjects: 40
Study 28081848 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 31
Study 28081848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 27696367 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B virus (HBV) infection
Number of subjects: 22215
Study 27696367 — intervention group
Group type: COMPARATOR
Intervention: Control group (no HBV infection)
Number of subjects: 22215
Study 24684456 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewable tablet (TAB)
Number of subjects: 66
Study 24684456 — intervention group
Group type: EXPERIMENTAL
Intervention: Oil-emulsified drop (DROP)
Number of subjects: 66
Study 24684456 — intervention group
Group type: EXPERIMENTAL
Intervention: Encapsulated powder (CAP)
Number of subjects: 66
Study 21933939 — intervention group
Group type: EXPERIMENTAL
Intervention: Final Kissing Ballooning (FKB)
Number of subjects: 1065
Study 21933939 — intervention group
Group type: COMPARATOR
Intervention: Non-Final Kissing Ballooning (non-FKB)
Number of subjects: 1065
Study 19120740 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal social rhythm therapy
Number of subjects: 1
Study 17634566 — intervention group
Group type: EXPERIMENTAL
Intervention: Affect labeling task
Number of subjects: 27
Study 17634566 — intervention group
Group type: COMPARATOR
Intervention: Gender labeling control task
Number of subjects: 27
Study 15117896 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1.5-2.55 g/day)
Number of subjects: 126
Study 11985913 — intervention group
Group type: EXPERIMENTAL
Intervention: Beraprost sodium (median dose 80 microg four times a day)
Number of subjects: 130
Study 11985913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 11229216 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed rest for 24 hours after lumbar puncture
Number of subjects: 208
Study 11229216 — intervention group
Group type: COMPARATOR
Intervention: Ambulant (no bed rest)
Number of subjects: 208
Study 7898228 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg twice daily (with triple therapy)
Number of subjects: 108
Study 7898228 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy without omeprazole
Number of subjects: 108
Study 2622545 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 40
Study 2622545 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone
Number of subjects: 40
Study 71495 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibre-free juice
Number of subjects: 10
Study 71495 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibre-disrupted purée
Number of subjects: 10
Study 71495 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact apples
Number of subjects: 10
Study 30893121 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous induction
Number of subjects: 0
Study 30893121 — intervention group
Group type: COMPARATOR
Intervention: Inhalational induction
Number of subjects: 0
Study 27549867 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg daily for 24 weeks
Number of subjects: 90
Study 27549867 — intervention group
Group type: COMPARATOR
Intervention: Finasteride 1 mg daily for 24 weeks
Number of subjects: 90
Study 25533393 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental behavioral economic intervention (SFAS)
Number of subjects: 97
Study 25533393 — intervention group
Group type: COMPARATOR
Intervention: Education control (EDU)
Number of subjects: 97
Study 25533393 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline values and change in RV
Number of subjects: 97
Study 23605225 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback treatment (30 sessions)
Number of subjects: 20
Study 23605225 — intervention group
Group type: COMPARATOR
Intervention: Usual maintenance treatment (Methadone or Buprenorphine)
Number of subjects: 20
Study 21832112 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean oil-based lipid emulsion (Intralipid)
Number of subjects: 12
Study 21832112 — intervention group
Group type: COMPARATOR
Intervention: Olive oil-based lipid emulsion (ClinOleic)
Number of subjects: 12
Study 21832112 — intervention group
Group type: COMPARATOR
Intervention: Lipid free PN
Number of subjects: 12
Study 21832112 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 12
Study 21832112 — intervention group
Group type: COMPARATOR
Intervention: Soybean oil PN, olive oil PN, and lipid free PN
Number of subjects: 12
Study 19626391 — intervention group
Group type: COMPARATOR
Intervention: 3 mg/kg infliximab
Number of subjects: 0
Study 19626391 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg infliximab
Number of subjects: 0
Study 19626391 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (3 mg/kg and 10 mg/kg infliximab)
Number of subjects: 0
Study 19626391 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher trough serum infliximab level
Number of subjects: 0
Study 17605449 — intervention group
Group type: EXPERIMENTAL
Intervention: Heel stick procedure
Number of subjects: 10
Study 17605449 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure (heel preparation with no heel puncture)
Number of subjects: 10
Study 15475488 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil, 50 mg
Number of subjects: 28
Study 15475488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 11319664 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of baseline total, flexible and rigid dietary restraint
Number of subjects: 0
Study 11319664 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline restraint measures
Number of subjects: 0
Study 11319664 — intervention group
Group type: EXPERIMENTAL
Intervention: Increases in restraint over the follow-up period
Number of subjects: 0
Study 9842184 — intervention group
Group type: EXPERIMENTAL
Intervention: Benecol margarine (cholesterol-lowering margarine with sitostanol ester)
Number of subjects: 0
Study 7989974 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ventricular function monitor with a cadmium telluride detector (CdTe‐VEST) during supine ergometric exercise
Number of subjects: 41
Study 3058796 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Na/High-K dietary salt
Number of subjects: 358
Study 3058796 — intervention group
Group type: COMPARATOR
Intervention: Common salt
Number of subjects: 358
Study 30168731 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil (50 mg acute dose)
Number of subjects: 0
Study 30168731 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (20 mg/day for 4 weeks)
Number of subjects: 0
Study 28031082 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose alendronate (70 mg per two weeks)
Number of subjects: 639
Study 28031082 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose alendronate (70 mg weekly)
Number of subjects: 639
Study 28031082 — intervention group
Group type: COMPARATOR
Intervention: Low dose and standard dose alendronate
Number of subjects: 639
Study 25645267 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermatologist's feedback on digital images of skin lesions
Number of subjects: 30
Study 25645267 — intervention group
Group type: COMPARATOR
Intervention: Feedback category 1 (no further investigation)
Number of subjects: 30
Study 25645267 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback category 3 (biopsy)
Number of subjects: 30
Study 25645267 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback category 2 (clinical observation)
Number of subjects: 30
Study 25645267 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback category 4 (other)
Number of subjects: 30
Study 24351994 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultural competence improvement program using case-based small group learning (n=31)
Number of subjects: 67
Study 24351994 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=36)
Number of subjects: 67
Study 20685525 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraction therapy (4 premolar extractions)
Number of subjects: 26
Study 20685525 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonextraction treatment with air-rotor stripping (ARS)
Number of subjects: 26
Study 20685525 — intervention group
Group type: COMPARATOR
Intervention: Both groups (extraction and nonextraction)
Number of subjects: 26
Study 17995982 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP plus intravitreal injection of 1.5 mg of bevacizumab
Number of subjects: 30
Study 17995982 — intervention group
Group type: COMPARATOR
Intervention: PRP
Number of subjects: 30
Study 16009290 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-based outpatient clinic follow-up (intervention group)
Number of subjects: 208